Sheets Smith Investment Management Boosts Holdings in Insulet Corporation $PODD

Sheets Smith Investment Management raised its stake in shares of Insulet Corporation (NASDAQ:PODD) by 48.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 4,641 shares of the medical instruments supplier’s stock after acquiring an additional 1,509 shares during the quarter. Insulet makes up 1.2% of Sheets Smith Investment Management’s investment portfolio, making the stock its 23rd largest position. Sheets Smith Investment Management’s holdings in Insulet were worth $1,219,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares in the last quarter. Groupama Asset Managment grew its holdings in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after buying an additional 3,759 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Insulet by 4.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock worth $177,096,000 after buying an additional 27,408 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Insulet by 27,298.6% during the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier’s stock worth $1,744,100,000 after buying an additional 661,717 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PODD. Canaccord Genuity Group upped their target price on shares of Insulet from $331.00 to $353.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Raymond James Financial reaffirmed an “outperform” rating and set a $360.00 target price (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They set a “buy” rating and a $380.00 price objective on the stock. Citigroup reissued a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $335.12.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Trading Up 0.1%

Shares of PODD opened at $337.94 on Friday. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $225.28 and a 12-month high of $353.50. The firm has a 50-day moving average price of $310.77 and a 200 day moving average price of $291.47. The firm has a market capitalization of $23.79 billion, a P/E ratio of 102.72, a P/E/G ratio of 2.80 and a beta of 1.36.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet’s quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.